Discontinuing Statins for Terminally Ill May Improve QOL

This article originally appeared here.
Share this content:
Discontinuing Statins for Terminally Ill May Improve QOL
Discontinuing Statins for Terminally Ill May Improve QOL

FRIDAY, March 27, 2015 (HealthDay News) -- Discontinuing the use of cholesterol-lowering statins in terminally ill patients may improve their quality of life, according to a new study published online March 23 in JAMA Internal Medicine.

The study included 381 patients, average age 74, who had late-stage cancer or other fatal illnesses and were taking statins. Half the patients stopped taking statins while the other half continued to take the drugs.

Median survival time for all the patients in the study was 219 days. The percentage of patients who died within 60 days was not significantly different between patients who kept taking statins and those who did not. "If the results we report -- improved quality of life, no significant differences in mortality, and modest cost savings -- had been produced by a randomized clinical trial of a new drug in patients with advanced life-limiting illness, the trial would be heralded as a breakthrough and there would be discussion of how to speed access to this new drug," the authors write.

"For patients with shorter life expectancy, greater concern about pill burden, and more comfort-oriented goals of care, physicians may endorse discontinuing statins as a means to reduce the number of medications without apparent harmful effects on survival or quality of life," first author Jean Kutner, M.D., of the University of Colorado School of Medicine in Aurora, and colleagues write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »